180608-78-0

Basic information

• Product Name: 1-(5-hydroxypentyl)-1H-pyrrole-2,5-dione
• CAS NO: 180608-78-0
• Molecular Weight: 183.207
• Mol File: 180608-78-0.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 1-(5-hydroxypentyl)-1H-pyrrole-2,5-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(5-hydroxypentyl)-1H-pyrrole-2,5-dione(180608-78-0)
• EPA Substance Registry System: 1-(5-hydroxypentyl)-1H-pyrrole-2,5-dione(180608-78-0)

Safety Data

• Hazardous Substances Data: 180608-78-0(Hazardous Substances Data)

Usage

Type of Compound

Derivative of neurotransmitter gamma-aminobutyric acid (GABA)

Potential Therapeutic Benefits

Treating neurological disorders such as epilepsy and anxiety
Exhibiting anti-seizure and anxiolytic (anti-anxiety) properties

Preclinical Studies

Shown to have positive effects on neurological conditions

Fields of Research

Neuroprotection and neuroregeneration

Current Status

Promising candidate for the development of new treatments for neurological disorders

Structure

Contains a pyrrole ring with a 5-hydroxypentyl side chain and two carbonyl groups at positions 2 and 5

Molecular Weight

Approximately 181.21 g/mol

Upstream product

• 55750-48-6 N-methoxycarbonylmaleimide 
• 2508-29-4 5-hydroxypentylamine 
• 915095-19-1 N-(5-O-t-butyldimethylsilyloxy pentyl)-maleimide 

Relevant articles and documents

A versatile acid-labile linker for antibody-drug conjugates

Antibody drug conjugates (ADC) couple therapeutic monoclonal antibodies (mAb) with potent toxins through a linker that is stable within systemic circulation, but cleaves within the target cells. In this report, silyl ether chemistry was used to couple the mAb trastuzumab with the chemotherapeutic, gemcitabine, to demonstrate the use of silyl ethers as a potential linker for ADCs.

SULFAMIDE LINKER, CONJUGATES THEREOF, AND METHODS OF PREPARATION

The present invention relates to a compound comprising an alpha-end and an omega-end, the compound comprising on the alpha-end a reactive group Qlcapable of reacting with a functional group F1present on a biomolecule and on the omega-end a target molecule, the compound further comprising a group according to formula (1) or a salt thereof: Said compound may also be referred to as a linker-conjugate. The invention also relates to a process for the preparation of a bioconjugate, the process comprising the step of reacting a reactive group Q1of a linker-conjugate according to the invention with a functional group F1of a biomolecule. The invention further relates to a bioconjugate obtainable by the process according to the invention. In a preferred embodiment, the invention concerns a process for the preparation of a bioconjugate via a cycloaddition, such as a (4+2)-cycloaddition (e.g. a Diels-Alder reaction) or a (3+2)-cycloaddition (e.g. a 1,3-dipolar cycloaddition).

Functionalized phosphonated half-cage molecules as ligands for metal complexes

Phosphonated molecules, featuring a half-cage structure and a N-lateral chain with additional metal coordinating groups were designed as ligands of metal cations. These compounds were synthesized by a Diels-Alder (DA) strategy, using 1-diethoxyphosphoryl-1,3-butadiene and a series of N-substituted maleimides as dienophiles. Two cycloadducts, bearing a terminal primary alcohol and a terminal iodide, respectively, were used as key intermediates for further functionalizations. Metal coordination properties of the ligands equipped with functionalized N-lateral chains were proven by an ESI-HRMS study. The stoichiometry of one selected EuIII complex with a diphosphonated ligand was determined by photoluminescence spectroscopy in emission mode.